๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Advanced Hodgkin Lymphoma

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies NCT07195916Phase 122 sites๐Ÿ“ Duarte๐Ÿ“ La Jolla๐Ÿ“ Ann Arbor Incyte Corporation ยท Tests: INCA036873 A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPฮฑ-CD47 Pathway, in Solid or Hematological Tumors NCT05892718Phase 18 sites๐Ÿ“ Port Saint Lucie๐Ÿ“ Huntersville๐Ÿ“ Greenville FBD Biologics Limited ยท Tests: HCB101 Odronextamab in Low Tumor Volume Advanced FL NCT07128641Phase 21 site๐Ÿ“ Boston Gottfried von Keudell, MD PhD ยท Tests: Odronextamab Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma NCT06745076Phase 26 sites๐Ÿ“ Irvine๐Ÿ“ Palo Alto๐Ÿ“ Boston University of Washington ยท Tests: Biospecimen Collection, Computed Tomography, Dacarbazine, Doxorubicin, Echocardiography Test A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674Phase 117 sites๐Ÿ“ Duarte๐Ÿ“ Los Angeles๐Ÿ“ San Francisco Nurix Therapeutics, Inc. ยท Tests: NX-1607, Paclitaxel JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma NCT07603479Phase 11 site๐Ÿ“ Beijing Jecho Biopharmaceuticals Co., Ltd. ยท Tests: JL19001, subcutaneous injection, 1 ฮผg/kg, JL19001, subcutaneous injection, 5 ฮผg/kg, JL19001, subcutaneous injection,10 โ€ฆ Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma NCT05949931Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Concurrent penpulimab and AVD, Sequential penpulimab and AVD Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naรฏve Advanced Stage Follicular Lymphoma NCT07126678NA1 site๐Ÿ“ Nanjing The First Affiliated Hospital with Nanjing Medical Universiโ€ฆ ยท Tests: zanubrutinib, bendamustine, and obinutuzumab Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma NCT06755450Phase 119 sites๐Ÿ“ Vadodara๐Ÿ“ Jhajjar๐Ÿ“ Bangalore Aurigene Discovery Technologies Limited ยท Tests: AUR112 Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL NCT07494565Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Celecoxib Combined with R-CHOP, R-CHOP Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies NCT04068597Phase 1, Phase 239 sites๐Ÿ“ Atlanta๐Ÿ“ Indianapolis๐Ÿ“ Bethesda CellCentric Ltd. ยท Tests: CCS1477, Pomalidomide, Dexamethasone, Azacitidine, Venetoclax Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) NCT03297606Phase 210 sites๐Ÿ“ Edmonton๐Ÿ“ Kelowna๐Ÿ“ Vancouver Canadian Cancer Trials Group ยท Tests: Olaparib, Dasatinib, Nivolumab plus Ipilimumab, Axitinib, Bosutinib An Engineered Sirpฮฑ Fused to Anti-Pd-L1 And Tgf-ฮฒ Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors NCT06487624Phase 17 sites๐Ÿ“ Greenville๐Ÿ“ Hangzhou๐Ÿ“ Hangzhou FBD Biologics Limited ยท Tests: HCB301 Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma NCT05833893Phase 21 site๐Ÿ“ Beijing Chinese PLA General Hospital ยท Tests: XPO1 inhibitor Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study NCT06534762Phase 21 site๐Ÿ“ Hangzhou Zhejiang Provincial People's Hospital ยท Tests: Mirabegron SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas NCT07222631Phase 1, Phase 21 site๐Ÿ“ La Jolla University of California, San Diego ยท Tests: SB-4826, Rituximab A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations NCT04094610Phase 1, Phase 268 sites๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles๐Ÿ“ Aurora Turning Point Therapeutics, Inc. ยท Tests: Oral repotrectinib (TPX-0005) A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1) NCT05984147Phase 127 sites๐Ÿ“ Visakhapatnam๐Ÿ“ Chandigarh๐Ÿ“ Ahmedabad Aurigene Discovery Technologies Limited ยท Tests: AUR108 IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers NCT06119685Phase 1, Phase 212 sites๐Ÿ“ Los Angeles๐Ÿ“ Lake Mary๐Ÿ“ Atlanta Indapta Therapeutics, INC. ยท Tests: IDP-023, Rituximab, Daratumumab, Interleukin-2, Cyclophosphamide Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial NCT05816850n/a26 sites๐Ÿ“ Alessandria๐Ÿ“ Biella๐Ÿ“ Brescia Fondazione Italiana Linfomi - ETS ยท Tests: EZH2 mutations/CNAs by droplet digital PCR (ddPCR), EZH2-derived gene expression signature by RNA-Seq Immunotherapy in Lymphoma NCT06796517n/a2 sites๐Ÿ“ Seoul๐Ÿ“ Seoul Sung-Soo Park ยท Tests: CAR-T Therapy, Bispecific antibody, Antibody-Drug Conjugate, Monoclonal antibody, Proteasome Inhibitor This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors NCT06451497Phase 13 sites๐Ÿ“ Boston๐Ÿ“ Austin, TX 78758๐Ÿ“ San Antonio Zumutor Biologics Inc. ยท Tests: ZM008 ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome NCT02848274n/a13 sites๐Ÿ“ Duarte๐Ÿ“ Palo Alto๐Ÿ“ Iowa City Stanford University A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) NCT02332668Phase 1, Phase 216 sites๐Ÿ“ Aurora๐Ÿ“ Chicago๐Ÿ“ Boston Merck Sharp & Dohme LLC ยท Tests: Pembrolizumab Study of AXT-1003 in Subjects With Advanced Malignant Tumors. NCT06484985Phase 15 sites๐Ÿ“ Beijing๐Ÿ“ Changsha๐Ÿ“ Fuzhou Axter Therapeutics (Beijing) Co., Ltd ยท Tests: AXT-1003 BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDAยฎ ) in Treatment of Advanced Malignancies(Keynote-D20) NCT04752826Phase 1, Phase 225 sites๐Ÿ“ Duarte๐Ÿ“ New York๐Ÿ“ Philadelphia BioInvent International AB ยท Tests: BI-1808, Pembrolizumab (KEYTRUDAยฎ ) 25 Mg/mL Solution for Injection, Paclitaxel 80 mg/m2 weekly Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) NCT01853631Phase 12 sites๐Ÿ“ Houston๐Ÿ“ Houston Baylor College of Medicine ยท Tests: Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells, Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells Studying TAK-243 in Patients With Advanced Cancer NCT06223542Phase 11 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas NCT05956041Phase 21 site๐Ÿ“ Ann Arbor University of Michigan Rogel Cancer Center ยท Tests: Pembrolizumab, Mogamulizumab Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET NCT06784752Phase 367 sites๐Ÿ“ Scottsdale๐Ÿ“ Fayetteville๐Ÿ“ Denver Novartis Pharmaceuticals ยท Tests: [177Lu]Lu-DOTA-TATE, Octreotide LAR
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy